Incidence of Oral Candidiasis, Prevalence of C. Dubliniensis in HIV Patients and In-vitro Azole Susceptibility (ICONIC)
( Dr. Vindas completed his fellowship + low enrollment )
University of Florida
Information provided by (Responsible Party)
University of Florida
First received: May 28, 2008
Last updated: May 7, 2015
Last Verified: May 2015
History of Changes
C. dubliniensis has been identified as pathogen in Oropharyngeal Candidiasis(OPC)particularly among HIV patients. Azole therapy is a cornerstone in OPC, but resistance within C. dubliniensis isolates to diflucan is common.This is a prospective collection of biological specimens from oropharyngeal cavity with the purpose of determining the prevalence of C. dubliniensis in HIV/AIDS patients at the Duval County Department of Health Comprehensive care Center. It is hereto proposed an estimation of azole-resistance in these isolates.
Time Perspective: Prospective
|Official Title:||Incidence of Oral Candidiasis, Prevalence of Candida Dubliniensis in HIV Patients and In-vitro Azole Susceptibility. (I.C.O.N.I.C.)|
Further study details as provided by University of Florida:
Primary Outcome Measures
- Incidence of oropharyngeal candidiasis in our HIV population; estimation of the prevalence of candida dubliniensis and pattern of azole resistance to direct future treatment [ Time Frame: April 2009 ]
|Study Start Date:||May 2008|
|Study Completion Date:||January 2009|
|Estimated Primary Completion Date:||October 2008 (Final data collection date for primary outcome measure)|
This is a study to try to establish the prevalence of C. dubliniensis as a causative organism
of OPC in HIV and/or AIDS patients. We will aim to establish the resistance pattern for
azoles but also for Flucytosine and amphotericin of these isolates.
This study will serve as a support to previously published articles that have suggested intrinsic azole-resistance within this particular species of candida and we will try to postulate its possible correlation with clinical failure.
|Ages Eligible for Study:||18 Years to 65 Years|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
|Sampling Method:||Non-Probability Sample|
Study PopulationHIV with or without AIDS defining illnesses at the Boulevard Comprehensive Care Center
- Any patient 18 years old or older with a documented diagnosis of HIV infection with or without AIDS-defining illnesses at the time of assessment, who is presenting with clinical symptoms and physical findings compatible with oropharyngeal candidiasis (as defined by the IDSA Guidelines for the Treatment and Management of HIV and HIV- related complications.
- Any prior diagnosis or established treatment for oropharyngeal, mucocutaneous or
Contacts and LocationsChoosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00692783
Locations Show More
|United States, Florida|
|Duval County Department of Health. Boulevard Comprehensive Care Center|
|Jacksonville, Florida, United States, 32206|
Sponsors and CollaboratorsUniversity of Florida
|Principal Investigator:||Jose Vindas, MD||University of Florida|
|Responsible Party:||University of Florida|
|ClinicalTrials.gov Identifier:||NCT00692783 History of Changes|
|Other Study ID Numbers:||UFJ2008-19|
|Study First Received:||May 28, 2008|
|Last Updated:||May 7, 2015|
Keywords provided by University of Florida:candida
Additional relevant MeSH terms:
ClinicalTrials.gov processed this data on June 15, 2018
This information is provided by ClinicalTrials.gov.